| 10/02/2026 3:42 PM | Quoin Pharmaceuticals (1671502) Filer | Form DEF 14A | |
| 09/27/2026 11:15 PM | Quoin Pharmaceuticals (1671502) Filer | Form EFFECT | |
| 09/25/2026 3:45 PM | Quoin Pharmaceuticals (1671502) Filer | Form 424B3 | |
| 09/22/2026 3:59 PM | Quoin Pharmaceuticals (1671502) Filer | Form PRE 14A | |
| 09/22/2026 3:15 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/18/2026 4:00 PM | Quoin Pharmaceuticals (1671502) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 09/10/2026 4:01 PM | Quoin Pharmaceuticals (1671502) Filer | Form D Notice of Exempt Offering of Securities | |
| 09/10/2026 3:05 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/01/2026 8:38 PM | Culverwell Anthony James (1693548) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/01/2026 8:39 PM | Lawlor Sally Bridget (2084407) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/01/2026 8:39 PM | Myers Michael (1959547) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for QNRX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/01/2026 8:40 PM | Carter Denise P. (1958621) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/28/2026 5:39 PM | Culverwell Anthony James (1693548) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/28/2026 5:40 PM | LANGER DENNIS (1274225) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/28/2026 9:31 AM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/20/2026 3:19 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 3:02 PM | Quoin Pharmaceuticals (1671502) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/16/2026 6:30 AM | Quoin Pharmaceuticals (1671502) Filer | Form DEF 14A | |
| 07/16/2026 6:35 AM | Quoin Pharmaceuticals (1671502) Filer | Form ARS | |
| 07/06/2026 4:21 PM | Quoin Pharmaceuticals (1671502) Filer | Form PRE 14A | |
| 06/23/2026 3:15 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/04/2026 3:04 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/02/2026 4:14 PM | INTEGRATED CORE STRATEGIES (0) US Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G | |
| 06/02/2026 5:06 AM | Quoin Pharmaceuticals (1671502) Filer | Form 424B3 | |
| 05/15/2026 7:16 PM | ADAR1 Capital Management, LLC (1940272) Filed by Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G/A | |
| 05/15/2026 4:23 PM | Quoin Pharmaceuticals (1671502) Subject Stonepine Capital Management, LLC (1440771) Filed by | Form SCHEDULE 13G/A | |
| 05/15/2026 8:13 AM | Quoin Pharmaceuticals (1671502) Subject Woodline Partners LP (1784547) Filed by | Form SCHEDULE 13G/A | |
| 05/07/2026 12:34 PM | Quoin Pharmaceuticals (1671502) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/29/2026 5:41 AM | Aberdeen Group plc (1716774) Filed by Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G/A | |
| 03/31/2026 12:59 PM | Quoin Pharmaceuticals (1671502) Issuer Stonepine Capital Management, LLC (1440771) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/26/2026 8:35 AM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/17/2026 7:14 PM | ADAR1 Capital Management, LLC (1940272) Filed by Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G | |
| 02/11/2026 4:10 PM | INTEGRATED CORE STRATEGIES (0) US Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G/A | |
| 02/06/2026 4:12 PM | Leong Natalie Ee Mun (1959318) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:14 PM | Quoin Pharmaceuticals (1671502) Issuer SEMBER MICHAEL T (1107486) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:15 PM | LANGER DENNIS (1274225) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:17 PM | Carter Denise P. (1958621) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:18 PM | Myers Michael (1959547) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:20 PM | Culverwell Anthony James (1693548) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:21 PM | Cooper Joseph Patrick (1368711) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 4:24 PM | Lawlor Sally Bridget (2084407) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Trump’s issues shocking Executive Order on U.S. Dollar (Ad) Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered.
Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18.
Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system. Read the full breakdown of Executive Order 14178 now |
| 02/06/2026 4:28 PM | Ikarian Capital, LLC (1778253) Filed by Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G/A | |
| 02/02/2026 7:00 PM | Quoin Pharmaceuticals (1671502) Issuer Stonepine Capital Management, LLC (1440771) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/02/2026 7:01 PM | Quoin Pharmaceuticals (1671502) Subject Stonepine Capital Management, LLC (1440771) Filed by | Form SCHEDULE 13G/A | |
| 01/28/2026 10:05 AM | Aberdeen Group plc (1716774) Filed by Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G | |
| 01/20/2026 4:18 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/16/2025 3:04 PM | Quoin Pharmaceuticals (1671502) Subject Stonepine Capital Management, LLC (1440771) Filed by | Form SCHEDULE 13G | |
| 12/15/2025 8:53 PM | Ikarian Capital, LLC (1778253) Filed by Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G | |
| 12/11/2025 9:10 AM | Quoin Pharmaceuticals (1671502) Subject Resolute Capital Asset Partners LLC (1834913) Filed by | Form SCHEDULE 13G | |
| 12/05/2025 7:00 AM | Quoin Pharmaceuticals (1671502) Filer | Form 424B3 | |
| 12/04/2025 11:15 PM | Quoin Pharmaceuticals (1671502) Filer | Form EFFECT | |
| 12/03/2025 4:39 PM | Lawlor Sally Bridget (2084407) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/17/2025 4:00 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/12/2025 7:00 AM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/07/2025 3:46 PM | Quoin Pharmaceuticals (1671502) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 11/06/2025 3:18 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/27/2025 3:32 PM | INTEGRATED CORE STRATEGIES (0) US Quoin Pharmaceuticals (1671502) Subject | Form SCHEDULE 13G | |
| 10/23/2025 3:57 PM | Quoin Pharmaceuticals (1671502) Filer | Form D Notice of Exempt Offering of Securities | |
| 10/21/2025 3:40 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/15/2025 4:15 PM | LANGER DENNIS (1274225) Reporting Quoin Pharmaceuticals (1671502) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/15/2025 3:15 PM | Quoin Pharmaceuticals (1671502) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |